Cornerstone Therapeutics (Nasdaq: CRTX) is revamping its board of directors following the completion of its merger with Critical Therapeutics.

The deal enabled Cornerstone, which had been privately held and known as Cornerstone BioPharma, to become a publicly traded company.

Craig Collard, chief executive of Cornerstone, will serve as board chairman. Alastair McEwan, who had been Cornerstone BioPharma, board chair, was also named to the merged company’s board.

Christopher Codeanne, chief financial officer at Oncology Development Partners, is joining the board along with Michael Enright and Michael Hefferman. Enright is CFO of Atlantic Search Group. Heffernan is CEO of Collegium Pharmaceutical.